No ongoing innovative drugs, JinYao Pharmaceutical hits 6 consecutive limit-ups!

Shares in innovative drugs have been strengthening recently. As of the time of this report, Tianjin Pharma Pharmaceutical Co., Ltd. has logged six consecutive daily limit-up moves.

In an announcement released after yesterday’s market close, Tianjin Pharma Pharmaceutical Co., Ltd. again issued a stock trading risk warning, saying it has noticed that the market has labeled the company as an “innovative drug” concept stock. The company’s current R&D focuses mainly on generic drugs, with no in-development innovative drug projects. Moreover, the company’s latest period operating performance has declined significantly, and the stock price increase has already deviated from the company’s underlying operating fundamentals.

For Tianjin Pharma Pharmaceutical Co., Ltd., in the first three quarters of 2025 it achieved operating revenue of RMB 2.23B, down 13.24% year over year. Net profit attributable to shareholders of the listed company was RMB 69.5399 million, down 62.75% year over year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 136 million, down 26.06% year over year.

With no in-development innovative drugs, why is it leading the pack in the innovative drug sector rally?

According to analysis by other media, Tianjin Pharma Pharmaceutical Co., Ltd.’s addition of the “innovative drug” concept likely stems from a response the company previously gave on an investor interaction platform. On September 5, 2025, Tianjin Pharma Pharmaceutical Co., Ltd. said in its reply to an investor question about innovation drug R&D progress that:

“JYSW003 is an innovative drug project commissioned by Tianjin Jinyu Biotechnology (Tianjin) Co., Ltd. to the company’s innovative research institute. The indication is psoriasis. Preliminary results from earlier exploratory research initially showed that the drug has significant efficacy and excellent safety characteristics. Currently, it is being carried out normally in accordance with the contract. In addition, the company established the innovative research institute in 2024, responsible for innovative drug design, discovery, R&D, and incubation and introduction work. At present, regarding the company’s innovative drug pipeline, projects are in the early exploratory research stage.”

But in last night’s announcement, Tianjin Pharma Pharmaceutical Co., Ltd. has already stated clearly that the company has no in-development innovative drug projects.

Tianjin Pharma Pharmaceutical Co., Ltd. is a leading domestic manufacturer of steroid hormone active pharmaceutical ingredients. Its main businesses include corticosteroid, sex hormone, anesthetic steroid hormones, and amino-acid-based API and preparations. It is one of the hormone API companies in Asia with the largest production capacity and the most complete product categories. Core products include prednisone, dexamethasone, methylprednisolone, and the series of betamethasone, among others.

Source of image: Tianjin Pharma Pharmaceutical Co., Ltd. semi-annual report

Tianjin Pharma Pharmaceutical Co., Ltd. said it will disclose its “2025 Annual Report” on April 25, 2026.

Tianjin Pharma Pharmaceutical Co., Ltd. reminds investors that market sentiment may currently be excessively hot and that there may be irrational speculation. The company’s fundamentals have not undergone major changes, and there is always a risk of a rapid decline.

Reference: 21st Century Business Herald, Eastmoney.com, Tianjin Pharma Pharmaceutical Co., Ltd. announcements

↓⭐ Follow Pharma Tong Media to gain insight into industry trends ↓

Submission / corporate cooperation / content communication:

Pharma Tong Media chief editor—Huaji Beauty (Ww_150525)

A massive amount of information and precise interpretation—available in the Sina Finance APP